Sphingolipid profile in the CNS of the twitcher (globoid cell leukodystrophy) mouse: a lipidomics approach.
Globoid cell leukodystrophy (Krabbe disease) is caused by mutations in galactosylceramidase, a lysosomal enzyme that acts to digest galactosylceramide, a glycolipid concentrated in myelin, and psychosine (galactosylsphingosine). Globoid cell leukodystrophy has been identified in many species including humans and twitcher mice. Several studies on human tissue have examined the lipid profile in this disease by gas, liquid or thin layer chromatography. Electrospray ionization tandem mass spectrometry combined with reverse phase HPLC has become a powerful alternative strategy, used here to compare the sphingolipid profile of pons/medulla tissue from twitcher mice with control tissue. In this lipidomics LC-MS approach, we scanned for precursors of m/z 264 to obtain a semi-quantitative profile of ceramides and galactosylceramides. Sphingosine-1-phosphate, C18:0 ceramide, C22:0 ceramide and C24:0 ceramide levels were reduced in the pons/medulla of twitcher mice compared to levels in control mice at 31 and 35-37 days of age. The levels of C22:0 and C24:0 galactosylceramide were similar between twitcher and control specimens and there was a trend toward reduced levels of C24:1 galactosylceramide and C24:1 hydroxy-galactosylceramide in twitcher specimens. Psychosine, C 16:0 ceramide and C 18:0 galactosylceramide levels were increased in the CNS of twitcher mice compared to levels in control mice. These data indicate that there is a trend toward decreased levels of long chain fatty acids and increased levels of shorter chain fatty acids in galactosylceramides and ceramides from twitcher mice compared with control mice, and such changes may be due to demyelination characteristic of acute pathology.
Esch
S W
SW
Mass Spectrometry Laboratory, University of Kansas, Lawrence, Kansas 66045, USA.
Williams
T D
TD
Biswas
S
S
Chakrabarty
A
A
LeVine
S M
SM
D000818:Animals; D002490:Central Nervous System / Q000737:chemistry* / Q000503:physiopathology; D002518:Ceramides / Q000032:analysis; D002851:Chromatography, High Pressure Liquid; D002853:Chromatography, Liquid; D004195:Disease Models, Animal; D005227:Fatty Acids / Q000032:analysis; D005699:Galactosylceramides / Q000032:analysis; D007965:Leukodystrophy, Globoid Cell / Q000378:metabolism* / Q000503:physiopathology; D008246:Lysophospholipids / Q000032:analysis; D013058:Mass Spectrometry; D008526:Medulla Oblongata / Q000737:chemistry / Q000503:physiopathology; D051379:Mice; D008810:Mice, Inbred C57BL; D008818:Mice, Neurologic Mutants; D011149:Pons / Q000737:chemistry / Q000503:physiopathology; D011609:Psychosine / Q000032:analysis; D013107:Sphingolipids / Q000032:analysis* / Q000737:chemistry / Q000302:isolation & purification; D013110:Sphingosine / Q000031:analogs & derivatives / Q000032:analysis
D002518:Ceramides; D005227:Fatty Acids; D005699:Galactosylceramides; D008246:Lysophospholipids; D013107:Sphingolipids; D011609:Psychosine; C060506:sphingosine 1-phosphate; D013110:Sphingosine